Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is a well-established and successful drug firm, with a strong focus on neuroscience, cardiometabolic, cancer, and immunology drugs. The positive OUS Mounjaro adoption and incremental Foundayo launch suggest continued growth for the company, and the expected launch of retatrutide in 2027 adds potential for future success. Some key risks for investors to consider include potential pricing pressure, underperformance of certain pipeline products, and competition from other drug companies.

Bears say

Eli Lilly is facing potential negative press and stock decline due to reported cases of liver failure associated with their drug Verzenio. This could lead to decreased sales and a negative impact on the company's financials, potentially causing a decline in stock performance. Despite recent model changes and positive revenue and EPS guidance, there is still significant risk and uncertainty surrounding Eli Lilly's products, particularly in the oncology and immunology sectors.

Eli Lilly (LLY) has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 20 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Jun 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,229.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,229.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.